The economic burden of toxicities associated with cancer treatment: Review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue

PharmacoEconomics

Volumn 31, Issue 9, 2013, Pages 753-766

  Carlotto, Alan ^a   Hogsett, Virginia L ^a   Maiorini, Elyse M ^a   Razulis, Janet G ^b   Sonis, Stephen T ^a,b  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; INFUSION FLUID; IRINOTECAN; OCTREOTIDE; OXALIPLATIN; PACLITAXEL;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC DISEASE; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; EMERGENCY WARD; FATIGUE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; MEDICAL FEE; MULTIPLE CYCLE TREATMENT; ORAL MUCOSITIS; OUTPATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ANTINEOPLASTIC AGENTS; DIARRHEA; FATIGUE; HEALTH CARE COSTS; HUMANS; NAUSEA; NEOPLASMS; RADIOTHERAPY; STOMATITIS; VOMITING;

EID: 84883550586     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0081-2     Document Type: Review

References (43)

1. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28.
2. Surveillance, Epidemiology and End Results (SEER) Database (2012). Lifetime risk (percent) of being diagnosed with cancer by site and race/ethnicity: males, 18 SEER areas, 2007-2009 (Table 1.15) and females, 18 SEER areas, 2007-2009 (Table 1.16). http://seer.cancer.gov/csr/1975-2009-pops09/ results-merged/topic-lifetime-risk-diagnosis.pdf. Accessed May 2013.
3. Kim E, Dodd MJ, Aouizerat BE, et al. A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manage. 2009;37(4):715-36.
4. Aprile G, Ramoni M, Keefe D, et al. Links between regimen-related toxicities in patients being treated for colorectal cancer. Curr Opin Support Palliat Care. 2009;3(1):50-4.
5. Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23(8):1986-92.
6. Haiderali A, Menditto L, Good M, et al. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer. 2011;19(6):843-51.
7. Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110(3):678-85. (Pubitemid 47106159)
8. Craver C, Gayle J, Balu S, et al. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ. 2011;14(1):87-98.
9. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19(1):131-40.
10. Hamada S, Hinotsu S, Hori K, et al. The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study. Support Care Cancer. 2012;20(4):813-20.
11. Lordick F, Ehlken B, Ihbe-Heffinger A, et al. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer. 2007;43(2):299-307. (Pubitemid 46123990)
12. Ballatori E, Roila F, Ruggeri B, et al. The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer. 2007;15(1):31-8. (Pubitemid 46088311)
13. Barrajon E, de las Peñas R. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron: a cost-benefit analysis. Support Care Cancer. 2000;8(4):323-33. (Pubitemid 30430057)
14. Hartmann JT, von Vangerow A, Fels LM, et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer. 2001;84(3):313-20. (Pubitemid 32154422)
15. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15(3):526-36. (Pubitemid 38444561)
16. Iihara H, Ishihara M, Matsuura K, et al. Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract. 2012;18(4):753-60.
17. Lachaine J, Yelle L, Kaizer L, et al. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther. 2005;2(3):181-7.
18. Elting L, Shih Y. The economic burden of supportive care of cancer patients. Support Care Cancer. 2004;12(4):219-26. (Pubitemid 38678556)
19. Mittmann N, Verma S, Koo M, et al. Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer. Curr Oncol. 2010;17(1):7-16.
20. Dranitsaris G, Maroun J, Shah A, et al. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy induced diarrhea. Can J Gastroenterol. 2005;19(2):83-7. (Pubitemid 40392721)
21. Dranitsaris G, Maroun J, Shah A, et al. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support Care Cancer. 2005;13(5):318-24. (Pubitemid 40674837)
22. Schwartzber LS, Sonis ST, Walker MS, et al. Single nucleotide polymorphism (SNP) Bayesian networks (BNs) predict risk of chemotherapy-induced side effects in patients with breast cancer receiving dose dense (DD) doxorubicin/cyclophosphamide plus paclitaxel (AC+T) [abstract no. 700107; poster no. P1-15-12]. San Antonio Breast Cancer Symposium; San Antonio; 4-8 Dec 2012.
23. Sonis ST, Schwartzber LS, Walker MS, et al. Predicting risk of chemotherapy-induced side effects in patients with colon cancer with single-nucleotide polymorphism (SNP) Bayesian networks (BNs). J Clin Oncol. 2012;30(Suppl 34);Abstract no. 344.
24. Arbuckle RB, Huber SL, Zacker C, et al. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist. 2000;5(3):250-9. (Pubitemid 30429944)
25. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531-9. (Pubitemid 37151510)
26. National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.0. Bethesda: US Department of Health and Human Services, National Institutes of Health; 2010.
27. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201-5. (Pubitemid 32372323)
28. Elting LS, Cooksley CD, Chambers MS, et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110-20. (Pubitemid 47048578)
29. Murphy BA, Beaumont JL, Isitt J, et al. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage. 2009;38(4):522-32.
30. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253-62. (Pubitemid 36556043)
31. Nonzee NJ, Dandade NA, Patel U, et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis. Cancer. 2008;113(6):1446-52.
32. Peterman A, Cella D, Glandon G, et al. Mucositis in head and neck cancer: economic and quality of life outcomes. J Natl Cancer Inst Monogr. 2001;29:45-51.
33. Aprile G, Pisa FE, Follador A, et al. Unplanned presentations of cancer outpatients: a retrospective cohort study. Support Care Cancer. 2013;21(2):397-404.
34. Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Nat Cancer Inst. 2006;98(16):1108-17. (Pubitemid 44288785)
35. McKenzie H, Hayes L, White K, et al. Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. Support Care Cancer. 2011;19(7):963-9.
36. Poirier Patricia. Factors affecting performance of usual activities during radiation therapy. Oncology Nursing Forum. 2007;34(4):827-34.
37. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist. 2000;5(5):353-60.
38. Lavigne JE, Griggs JJ, Tu XM, et al. Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivors. J Cancer Surviv. 2008;2(4):296-302.
39. Lee MK, Lee KM, Bae JM, et al. Employment status and work-related difficulties in stomach cancer survivors compared with the general population. British J Cancer. 2008;98(4):708-15. (Pubitemid 351272622)
40. Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer. 2011;19:1421-7.
41. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse events? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22:3485-90. (Pubitemid 41103654)
42. Ihbe-Heffinger A, Paessens B, Berger K, et al. The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care - an observational analysis on non-small-cell lung cancer patients. Support Care Cancer (Epub 2013 Jan 23).
43. Poirier P. The relationship of sick leave benefits, employment patterns, and individual characteristics to radiation therapy-related fatigue. Oncol Nurs Forum. 2006;33(3):593-601. (Pubitemid 44870227)